Short Interest in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Grows By 19.5%

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the target of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 4,900 shares, a growth of 19.5% from the February 13th total of 4,100 shares. Based on an average daily trading volume, of 33,200 shares, the short-interest ratio is currently 0.1 days. Currently, 0.3% of the shares of the company are sold short.

Hedge Funds Weigh In On Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC purchased a new position in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned 3.97% of Galmed Pharmaceuticals at the end of the most recent quarter. 76.14% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on Galmed Pharmaceuticals in a report on Wednesday, March 12th. They issued a “sell” rating for the company.

Galmed Pharmaceuticals Stock Up 0.4 %

Shares of GLMD stock traded up $0.01 on Tuesday, hitting $2.51. The company had a trading volume of 693,710 shares, compared to its average volume of 895,050. The firm has a market cap of $1.62 million, a P/E ratio of -0.15 and a beta of 0.72. The company has a 50-day moving average price of $2.52 and a 200-day moving average price of $3.44. Galmed Pharmaceuticals has a twelve month low of $1.67 and a twelve month high of $23.80.

Galmed Pharmaceuticals Company Profile

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.